BACKGROUND: The lack of agreement regarding what constitutes successful treatment for periprosthetic joint infections (PJI) makes it difficult to compare the different strategies of management that are used in clinical practice and in research studies. QUESTIONS/PURPOSES: The aims of this study were to create a consensus definition for success after PJI treatment, and to provide a universal, multidimensional framework for reporting of studies regarding PJI treatment. METHODS: A two-round basic Delphi method was used to reach a consensus definition. We invited 159 international experts (orthopaedic surgeons, infectious disease specialists, and clinical researchers) from 17 countries to participate; 59 participated in the first round, and 42 participated in the second round. The final definition consisted of all statements that achieved strong agreement (80% or greater of participants considering a criterion relevant for defining success). RESULTS: The consensus definition of a successfully treated PJI is: (1) infection eradication, characterized by a healed wound without fistula, drainage, or pain, and no infection recurrence caused by the same organism strain; (2) no subsequent surgical intervention for infection after reimplantation surgery; and (3) no occurrence of PJI-related mortality (by causes such as sepsis, necrotizing fasciitis). The Delphi panel agreed to defining midterm results as those reported 5 or more years after the definitive PJI surgery, and long-term results as those reported 10 or more years after surgery. Although no consensus was reached on the definition of short-term results, 71% of the participants agreed that 2 years after the definitive PJI surgery is acceptable to define it. CONCLUSIONS: This multidimensional definition of success after PJI treatment may be used to report and compare results of treatment of this catastrophic complication. LEVEL OF EVIDENCE: Level V, therapeutic study. See Guidelines for Authors for a complete description of levels of evidence.
BACKGROUND: The lack of agreement regarding what constitutes successful treatment for periprosthetic joint infections (PJI) makes it difficult to compare the different strategies of management that are used in clinical practice and in research studies. QUESTIONS/PURPOSES: The aims of this study were to create a consensus definition for success after PJI treatment, and to provide a universal, multidimensional framework for reporting of studies regarding PJI treatment. METHODS: A two-round basic Delphi method was used to reach a consensus definition. We invited 159 international experts (orthopaedic surgeons, infectious disease specialists, and clinical researchers) from 17 countries to participate; 59 participated in the first round, and 42 participated in the second round. The final definition consisted of all statements that achieved strong agreement (80% or greater of participants considering a criterion relevant for defining success). RESULTS: The consensus definition of a successfully treated PJI is: (1) infection eradication, characterized by a healed wound without fistula, drainage, or pain, and no infection recurrence caused by the same organism strain; (2) no subsequent surgical intervention for infection after reimplantation surgery; and (3) no occurrence of PJI-related mortality (by causes such as sepsis, necrotizing fasciitis). The Delphi panel agreed to defining midterm results as those reported 5 or more years after the definitive PJI surgery, and long-term results as those reported 10 or more years after surgery. Although no consensus was reached on the definition of short-term results, 71% of the participants agreed that 2 years after the definitive PJI surgery is acceptable to define it. CONCLUSIONS: This multidimensional definition of success after PJI treatment may be used to report and compare results of treatment of this catastrophic complication. LEVEL OF EVIDENCE: Level V, therapeutic study. See Guidelines for Authors for a complete description of levels of evidence.
Authors: Craig Della Valle; Javad Parvizi; Thomas W Bauer; Paul E Dicesare; Richard Parker Evans; John Segreti; Mark Spangehl; William C Watters; Michael Keith; Charles M Turkelson; Janet L Wies; Patrick Sluka; Kristin Hitchcock Journal: J Am Acad Orthop Surg Date: 2010-12 Impact factor: 3.020
Authors: Bassam A Masri; Kostas P Panagiotopoulos; Nelson V Greidanus; Donald S Garbuz; Clive P Duncan Journal: J Arthroplasty Date: 2007-01 Impact factor: 4.757
Authors: Steven M Kurtz; Edmund Lau; Jordana Schmier; Kevin L Ong; Ke Zhao; Javad Parvizi Journal: J Arthroplasty Date: 2008-04-10 Impact factor: 4.757
Authors: S Dovas; V Liakopoulos; L Papatheodorou; I Chronopoulou; V Papavasiliou; E Atmatzidis; M Giannopoulou; T Eleftheriadis; T Simopoulou; T Karachalios; I Stefanidis Journal: Clin Nephrol Date: 2008-03 Impact factor: 0.975
Authors: Jaiben George; Grzegorz Kwiecien; Alison K Klika; Deepak Ramanathan; Thomas W Bauer; Wael K Barsoum; Carlos A Higuera Journal: Clin Orthop Relat Res Date: 2016-07 Impact factor: 4.176
Authors: Mitchel D Armstrong; Alberto V Carli; Hesham Abdelbary; Stephane Poitras; Peter Lapner; Paule E Beaulé Journal: Can J Surg Date: 2018-02 Impact factor: 2.089
Authors: Linsen T Samuel; Assem A Sultan; Matthew Kheir; Jesus Villa; Preetesh Patel; Javad Parvizi; Carlos A Higuera Journal: Clin Orthop Relat Res Date: 2019-07 Impact factor: 4.176
Authors: Daniel J Cunningham; Joseph J Kavolus; Michael P Bolognesi; Samuel S Wellman; Thorsten M Seyler Journal: J Arthroplasty Date: 2017-01-26 Impact factor: 4.757
Authors: Charlotte Bielefeld; Harald Engler; Marcus JÄger; Alexander Wegner; Dennis Wassenaar; Andre Busch Journal: In Vivo Date: 2021 Mar-Apr Impact factor: 2.155
Authors: Daniel J Cunningham; Joseph J Kavolus; Michael P Bolognesi; Samuel S Wellman; Thorsten M Seyler Journal: J Arthroplasty Date: 2017-03-31 Impact factor: 4.757